KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-cash Items (2016 - 2025)

Regeneron Pharmaceuticals has reported Non-cash Items over the past 17 years, most recently at $326.1 million for Q4 2025.

  • Quarterly results put Non-cash Items at $326.1 million for Q4 2025, down 5.51% from a year ago — trailing twelve months through Dec 2025 was $474.0 million (up 5900.0% YoY), and the annual figure for FY2025 was $474.0 million, up 5900.0%.
  • Non-cash Items for Q4 2025 was $326.1 million at Regeneron Pharmaceuticals, up from $158.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for REGN hit a ceiling of $1.8 billion in Q3 2021 and a floor of -$2.5 billion in Q2 2021.
  • Median Non-cash Items over the past 5 years was $125.0 million (2021), compared with a mean of $40.2 million.
  • Biggest five-year swings in Non-cash Items: plummeted 5462.69% in 2021 and later soared 593.71% in 2024.
  • Regeneron Pharmaceuticals' Non-cash Items stood at $143.5 million in 2021, then surged by 264.32% to $522.8 million in 2022, then plummeted by 113.37% to -$69.9 million in 2023, then soared by 593.71% to $345.1 million in 2024, then fell by 5.51% to $326.1 million in 2025.
  • The last three reported values for Non-cash Items were $326.1 million (Q4 2025), $158.7 million (Q3 2025), and -$247.2 million (Q2 2025) per Business Quant data.